312 results about "Cell immune response" patented technology

Compositions and methods are provided for the treatment of infections by microbes associated with a latent infection.

Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.

The invention relates to a method for preparing the conspecific allo vessel de-cell support, which comprises that using the abdominal aorta of rabbit of New Zealand, using surface activator Triton X-100 to extract the liposome of cell membrane, and digesting the parenzyme, using nuclease DNAse and RNAse to degrade the DNA and RNA of cell, to obtain the support. The invention uses the similar structures of conspecific allo materials, with better histocompatibility, to support healing after surgery, with simple preparation and high efficiency. And the invention can be transplanted with low caused immunity reaction of host, to supply physical strength and tension. The invention can be used to replace blood vessel.

The invention discloses an Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and a preparation method thereof. The recombinant vaccine comprises the following components: proteins coded by foot-and-mouth disease virus multi-epitope genes and the fusion genes of carrier proteins, and foot-and-mouth disease virus 3D proteins. The preparation method comprises the following steps: diluting the proteins expressed by the foot-and-mouth disease virus multi-epitope genes and the fusion genes of the carrier proteins and the foot-and-mouth disease virus 3D proteins, mixing the diluted proteins uniformly, adding an adjuvant into the mixture to emulsify the mixture. Animal models and animal immune effect experiments show that the bovine Asia1 epitope recombinant vaccine can make comprehensive immune protective response, can induce injected and immunized bovine and guinea pigs to generate high level neutralizing antibodies, and can also induce cell immune response, so the recombinant vaccine can effectively protect animals against the virulent attack of the foot-and-mouth disease viruses.

The invention discloses a method for detecting a pathogenic microorganism by using antigen-stimulated cellular immune response. In the method, immune cells, which have been exposed to the microorganism, in blood are stimulated by specific antigen of the pathogenic microorganism or a functional segment of the pathogenic microorganism, so a cell factor, such as interferon gamma (IFN-gamma), is produced by the immune cells; and then whether the pathogenic microorganism exists in animals is judged by detecting the amount of the IFN-gamma. In the invention, the IFN-gamma in the blood is detected by a colloidal gold-labeled immunochromatographic assay. In addition, the invention also discloses a colloidal gold immunochromatographic assay test pen for detecting the pathogenic microorganism. By the method, the pathogenic microorganism in an incubation period or early morbidity can be detected quickly and effectively.

The invention relates to the technical field of biomedicine, and particularly provides a fusion protein of an SVV and an FMDV, an encoding gene of the fusion protein, an expression vector, a cell line, engineering bacteria, a vaccine and application. The fusion protein is obtained by replacing an epitope capable of inducing the body to produce a neutralizing antibody with a decoy epitope and comprises SVV VP1 protein fragments, FMDV VP1 protein fragments and complement C3d protein fragments. The fusion protein combines antigens for inducing the body to produce the neutralizing antibody, of twopathogens of SVV and FMDV, and the safety of the antigens is improved while the antigenic epitopes of the SVV and the FMDV are reserved. The complement C3d molecules can excite nonspecific body fluidand cellular immune reactions in the body, and play an important role in increasing the antibody titer of the vaccine, and activating the cellular immune response of the body. The vaccine prepared bymeans of the fusion protein is safe and effective, and hydroa and foot-and-mouth diseases can be effectively prevented.

The invention belongs to the field of animal biomedicine engineering, and in particular discloses protein recombinant lactococcus lactis for secretory expression of a core antigen COE of a PEDV (Porcine Epidemic Diarrhea Virus) as well as a preparation method and an application of the protein recombinant lactococcus lactis. The method comprises the following steps: connecting a signal peptide and other sequences onto a gene of the core antigen COE of the PEDV via an overlap extension PCR method by designing multiple primers, connecting the gene to a lactococcus lactis expression vector pNZ8048 and introducing the vector with the gene into a cell of the lactococcus lactis NZ9000 in an electrotransformation manner so as to obtain recombinant bacteria; and inducing the recombinant bacteria with nisin so as to obtain an expression, and directly taking all induced cultures as oral vaccines capable of stimulating mice and inducing strong cellular immune responses. Thus, the protein recombinant lactococcus lactis can serve as a novel oral vaccine product with a good industrial prospect and has a positive effect for reducing harms of the PEDV to pig industry, thereby playing a great practical significance for promoting the healthy development of the pig industry.

The invention relates to a hepatitis B virus nucleic acid vaccine optimized by codon. In the invention, hepatitis B surface antigen (HBs) gene order (adr subtype) is analyzed to find codon locus which tells the differences between the codon preferences of the gene order and the codon preferences of the mammal; the codon of the HBs gene order is replaced to obtain the surface antigen gene; the gene order is combined and expanded to obtain MHBs, Pst I, BamH I, double digestion MHBs gene and carrier pSW3891 plasmid optimized by the codon; 10ul connection system is configured to obtain a middle protein gene. The nucleic acid vaccine of the invention overcomes the defects that the differences between prokaryote and eukaryote in terms of codon preferences cause that the foreign gene can not be expressed effectively in mammal reservoir and can not generate relatively good immune sheltering effect; in addition, the invention remarkably improve protein expression of the foreign gene in the mammal reservoir, effectively stimulates immune system of the reservoir to generate relatively good immunological reaction of human body fluids and cellular immune response.

The invention belongs to the field of biological medicine engineering, and particularly discloses a preparation method of an oral subunit vaccine for a porcine epidemic diarrhea virus. The prepared subunit vaccine can be directly used as an oral vaccine to immune a mouse, and the mouse can be stimulated to generate stronger humoral immune response and cellular immune response. The vaccine is not degraded easily in the stomach and intestines, the immune effect is remarkable, the preparation process is simple, and the oral subunit vaccine plays an active role in relieving harm caused by the porcine epidemic diarrhea virus to the pig industry and has important practical significance in promoting healthy development of the pig industry.

The invention discloses a fusion protein for Micrococcus pyogenes surface protein, and also discloses the method for preparing the same as well as its usage. The fusion protein is fused by Micrococcus pyogenes fnb and thioredoxin Trx on expression carrier, and the process comprises preparation of Micrococcus pyogenes surface protein fnb coding gene, colony of fnb coding gene into expression carrier and protein fusion. The fusion protein is soluble protein and retains immunity of natural protein. It is detected that said fusion protein is characterized by good response for humoral immunity and cell immunity, enlargement of protection range of protein vaccine and prevention of infection caused by most of Micrococcus pyogenes.

The invention relates to the field of molecular biology and immunology, in particular to an application of an HBcAg (hepatitis B core antigen) virus-like particle serving as a cervical cancer therapeutic vaccine carrier. A preparation method comprises steps as follows: an HPV16 E749-57CTLs epitope peptide fragment is selected, a DNA (deoxyribose nucleic acid ) fragment of the HPV16 E749-57CTLs epitope peptide fragment is inserted between 78 and 79 amino acids of the HBcAg through genetic recombination, an obtained recombinant plasmid pHBcAg-E749-57 is converted into Escherichia coli DH5alpha, and an HBcAg virus-like particle vaccine presenting E749-57 is obtained after induction expression and purification. After a tumor-bearing mouse is immunized with the virus-like particle vaccine, the body of the mouse can be induced to generate a higher HPV16E7 specific cellular immunologic response, and growth of tumors is remarkably inhibited.

The invention discloses a manually-combined Newcastle diseases virus F gene and a recombining expression vector and an application thereof. Codons of NDVF gene OFR are all replaced into chicken bias codons, EcoR V restriction sites and Kozak sequences are added upstream, Xbal I restriction sites and TGA stop codons are added downstream, and downstream bases A of the stop codons are changed into G, obtained genes (SEQ, ID NO: 2) can be efficiently expressed in eukaryotic cells, and the expression efficiency of the obtained genes is higher than that of wild type genes. Expressed genes have immunogenicity and biologic activity of natural protein of Newcastle diseases virus, can stimulate chicken to generate body fluid stronger immunologic response and stronger cell immunologic response than the wild F gene DNA vaccine so as to enable immunized chicken to obtain 100 percent of resistance to fatal attack of high-pathogenicity Newcastle strains, and can effectively inhibit the propagation of the virus in the chicken.

The invention relates to mouthwash prepared in a Chinese medical formula, and has the functions of replenishing qi, strengthening the spleen, tonifying the kidney, soothing the nerves, clearing the heat, detoxicating, clearing the damp, reducing the cellular immune response, the capillary permeability and the inflammatory exudates, and improving the immunity of the organism. The invention has the advantages of good treatment effect, high cure rate and no recurrence fundamentally; and the oral drug not only has good preventive effect, but also has good therapeutic effect.

The invention relates to preparation and application of DNA vaccine that can resist to the infection of hepatitis C virus. The invention constructed a recombinant DNA vaccine that can express HCV enveloped glycoprotein E1 with molecular cloning techniques, on this basis constructed six N-glycosylation mutants M1-M6 of the E1 and select N-glycosylation mutant M2 as DNA vaccine that resist to infection of hepatitis C virus and application in the preparation of DNA vaccine that prevent the HCV virus infection. The advantages of the invention are : experiments reveal that N-sugar chain of HCV E1 enveloped glycoprotein can limit the host's cellular immune responses, its glycosylation may shield the T and B cell epitope of virus, thereby enable the virus to evade immune recognition; with E1 glycosylate mutants M2 may be used as DNA vaccines that are HCV therapeutic and preventive and enhance the immunogenicity, besides preparation of mutants M2 E1 glycosylate is simple, convenient and effective, and has good application prospect.

The invention relates to a mimic eptitope peptide of BAFF-R and a DNA coding the peptide and the application of the mimic eptitope peptide in the preparation of antitumor bacterins and drugs. The mimic eptitope of 7 amino acids of BAF-R is a mimic eptitope of molecule BAFF-R with high affinity with a monoclonal antibody of BAFF-R, and is obtained through selection from a phage random display 7-peptide bank with a monoclonal antibody of BAFF-R as the antigen, wherein the sequence of the amino acids is Gly Tyr Thr Arg Trp Gly Cys. The 7-amino-acid mimic eptitope can also be used to construct a poly-peptide vaccine. The clonal inhibition rates of the phage display peptide provided by the invention are all more than 50 percent, and can specifically inhibit the combination between antibody and antigen for a larger extent, greatly improve the proliferation of mouse spleen lymphocytes without adjuvant, the mimic antigen is good in immunogenicity, as illustrated by the induced cell immune response after mice are vaccinated with the mimic antigen.

The invention discloses a CTL (Cytotoxic T Lymphocyte) epitope peptide of a foot-and-mouth disease virus type O as well as a screening method and application of the CTL epitope peptide. The CTL epitope peptide is composed of nine amino acid residues, and the amino acid sequence of the CTL epitope peptide is as follows: Ala-Thr-Arg-Val-Thr-Glu-Leu-Leu-Tyr. The epitope peptide has relatively strong combining capacity with SLA (Swineleukocyteantigen)-I proteins from various strains of swine and can induce cytotoxic immune response so as to be suitable for preparing vaccines for preventing and controlling foot-and-mouth disease viruses of various strains of swine and wide in application range. According to the invention, a CTL simulated epitope peptide of a foot-and-mouth disease virus is combined with a single-chain molecule of SLA-I of six strains of constructed swine in vitro, thus a polypeptide which can be combined with a complex can be screened through mass spectrum measurement; in addition, a simulated epitope peptide which can be induced to generate the immune response capacity of T cells is determined through ELISPOT (Enzyme-Linked Immunospot Assay) detection. The invention provides a method for screening and authenticating the CTL epitope of the foot-and-mouth disease virus in a large scale, and lays the foundation for researching and preparing a multi-epitope vaccine of a foot-and-mouth disease.

The hepatitis B treating vaccine preparation includes recombinant hepatitis B vaccine 40-80 microgram/ml and aluminum 0.5 mg/ml. The preparation process, use and composition of the hepatitis B treating vaccine are also disclosed. The preparation can induce cell immune response for body to eliminate HBV, increase the cell immunity of Balb/c mouse, promote the high level expression of Th1 cell factor, raise T proliferation level and raise specific CTL activity.

The invention discloses type A foot-and-mouth disease CTL (cytotoxic T lymphocyte) epitope peptide and a screening method thereof. The CTL epitope peptide consists of nine amino acid residues, and has an amino acid sequence of Ala-Met-Leu-Arg-Ala-Ala-Thr-Tyr-Tyr. The epitope peptide has stronger combining capability with SLA (swine leukocyte antigen)-?? proteins from pigs with different strains and causees cell toxicity immune response, and is applicable to the preparation of prevention and treatment vaccines for foot-and-mouth disease virus of pigs with various strains and wide in application range. According to the type A foot-and-mouth disease CTL epitope peptide and the screening method thereof, constructed SLA-I single-stranded molecules of pigs with six strains are utilized for in vitro combination with CTL simulated epitope peptide of foot-and-mouth disease virus, polypeptide which can be combined with complex is determined and screened by using a mass spectrum, and simulated epitope peptide which can induce the production of T cell immune response capability is determined through ELISPOT (enzyme linked immunospot assay) detection. The invention provides a method for screening and identifying a large number of foot-and-mouth disease virus CTL epitopes in the future, and lays a foundation for the development of multi-epitope vaccines for the foot-and-mouth disease of pigs.